{"id":"https://openalex.org/W2906336780","doi":"https://doi.org/10.1183/13993003.congress-2018.oa1940","title":"Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study","display_name":"Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study","publication_year":2018,"publication_date":"2018-09-15","ids":{"openalex":"https://openalex.org/W2906336780","doi":"https://doi.org/10.1183/13993003.congress-2018.oa1940","mag":"2906336780"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2018.oa1940","doi":"https://doi.org/10.1183/13993003.congress-2018.oa1940","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2018.oa1940","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Brian Maurer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Maurer","raw_affiliation_strings":["Verona Pharma, plc, New York, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verona Pharma, plc, New York, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068917661","display_name":"Dave Singh","orcid":"https://orcid.org/0000-0001-8918-7075","observed_orcids":["https://orcid.org/0000-0001-8918-7075"]},"institutions":[{"id":"https://openalex.org/I4210151016","display_name":"Medicines Evaluation Unit","ror":"https://ror.org/05e497m36","country_code":"GB","type":"other","lineage":["https://openalex.org/I4210151016"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dave Singh","raw_affiliation_strings":["Medicines Evaluation Unit, Manchester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medicines Evaluation Unit, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4210151016"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100767595","display_name":"Fernando J. Mart\u00ednez","orcid":"https://orcid.org/0000-0002-2412-3182","observed_orcids":["https://orcid.org/0000-0002-2412-3182","https://orcid.org/0000-0003-4957-8869","https://orcid.org/0000-0001-8298-2703"]},"institutions":[{"id":"https://openalex.org/I4387153466","display_name":"Weill Cornell Medicine","ror":"https://ror.org/02r109517","country_code":"US","type":"education","lineage":["https://openalex.org/I205783295","https://openalex.org/I4387153466"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fernando Martinez","raw_affiliation_strings":["Weill Cornell Medical College, New York, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Weill Cornell Medical College, New York, United States of America","institution_ids":["https://openalex.org/I4387153466"]}]},{"author_position":"last","author":{"id":null,"display_name":"Kenneth Newman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kenneth Newman","raw_affiliation_strings":["Verona Pharma, plc, New York, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verona Pharma, plc, New York, United States of America","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"OA1940","last_page":"OA1940"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.008100000210106373,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12434","display_name":"Phosphodiesterase function and regulation","score":0.002899999963119626,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.9380000233650208},{"id":"https://openalex.org/keywords/bronchodilation","display_name":"bronchodilation","score":0.9769999980926514},{"id":"https://openalex.org/keywords/copd-symptoms","display_name":"COPD symptoms","score":0.6179999709129333},{"id":"https://openalex.org/keywords/inhaled-medications","display_name":"inhaled medications","score":0.546999990940094},{"id":"https://openalex.org/keywords/anti-inflammatory-activity","display_name":"anti-inflammatory activity","score":0.5720000267028809},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.6660000085830688},{"id":"https://openalex.org/keywords/fev1","display_name":"FEV1","score":0.6869999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9422799348831177},{"id":"https://openalex.org/C2777394947","wikidata":"https://www.wikidata.org/wiki/Q410358","display_name":"Salbutamol","level":3,"score":0.8519779443740845},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7839643955230713},{"id":"https://openalex.org/C2908646376","wikidata":"https://www.wikidata.org/wiki/Q927234","display_name":"Bronchodilation","level":4,"score":0.7819929122924805},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.750535786151886},{"id":"https://openalex.org/C2781018748","wikidata":"https://www.wikidata.org/wiki/Q927234","display_name":"Bronchodilator","level":3,"score":0.6780936121940613},{"id":"https://openalex.org/C2776780178","wikidata":"https://www.wikidata.org/wiki/Q199804","display_name":"COPD","level":2,"score":0.6721745133399963},{"id":"https://openalex.org/C2780333948","wikidata":"https://www.wikidata.org/wiki/Q653305","display_name":"Spirometry","level":3,"score":0.6361783146858215},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.5586141347885132},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.498457670211792},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37367114424705505},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.16064321994781494},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2018.oa1940","doi":"https://doi.org/10.1183/13993003.congress-2018.oa1940","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2018.oa1940","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2555205291","https://openalex.org/W2552270172","https://openalex.org/W2552900327","https://openalex.org/W2898993591","https://openalex.org/W2889533372","https://openalex.org/W2109143421","https://openalex.org/W1846540661","https://openalex.org/W7136033282","https://openalex.org/W7136060134","https://openalex.org/W2970258188"],"abstract_inverted_index":{"Introduction:":[0],"RPL554":[1,28,72,119,192,202,216],"is":[2],"an":[3,125],"inhaled":[4],"dual":[5],"PDE3/4":[6],"inhibitor":[7],"that":[8],"showed":[9,165],"bronchodilator":[10],"and":[11,25,85,93,107,173,204,211,227,230,240],"anti-inflammatory":[12],"effects":[13,24],"in":[14,33,129,150,177,188,199,209,233,242],"prior":[15],"clinical":[16],"studies.":[17],"This":[18,40],"Phase":[19],"2b":[20],"study":[21],"investigated":[22],"the":[23,116,237],"tolerability":[26],"of":[27,51,67,70,135,155],"treatment":[29],"for":[30,166],"4":[31,134,221,238],"weeks":[32,239],"moderate":[34],"to":[35,64,87,157,255],"severe":[36],"COPD":[37,53,179,234],"patients.":[38],"Methods:":[39],"was":[41,82,98,185,224,253],"a":[42,145,169,225],"double-blind,":[43],"placebo":[44,78],"controlled,":[45],"parallel":[46],"group":[47],"study.":[48,117],"A":[49],"total":[50,178],"403":[52],"patients":[54],"(mean":[55],"age":[56],"63.2":[57],"years)":[58],"were":[59,62,197],"enrolled.":[60],"Patients":[61],"randomized":[63],"receive":[65],"one":[66],"four":[68],"doses":[69,120,142,168],"nebulised":[71],"(0.75mg,":[73],"1.5mg,":[74],"3mg,":[75],"6mg)":[76],"or":[77],"twice":[79],"daily.":[80],"Spirometry":[81],"performed":[83],"pre-dose":[84],"up":[86],"12h":[88],"post-dose":[89],"at":[90,132,136,249],"day":[91],"1":[92],"week":[94,133],"4.":[95],"Holter":[96,212],"monitoring":[97],"performed.":[99],"An":[100],"electronic":[101],"diary":[102,164],"recorded":[103],"daily":[104],"symptoms":[105,180,235],"(E-RS)":[106],"rescue":[108,243],"salbutamol":[109,244],"use.":[110,245],"Results:":[111],"375":[112],"subjects":[113],"(92.6%)":[114],"completed":[115],"All":[118,141],"produced":[121],"significant":[122,146,170,229],"bronchodilation":[123,219],"with":[124,206],"increase":[126,147],"from":[127,148],"baseline":[128,149],"peak":[130],"FEV1":[131,154],"least":[137],"200":[138],"mL":[139],"(p<0.001).":[140],"also":[143],"caused":[144,217],"average":[151],"AUC0-12":[152],"hour":[153],"65":[156],"119":[158],"ml":[159],"(p<0.05).":[160],"The":[161,246],"E-RS":[162],"symptom":[163],"all":[167,189,250],"(p\u22640.002),":[171],"progressive":[172,231],"clinically":[174,226],"relevant":[175],"reduction":[176,241],"(>2":[181],"units).":[182],"Salbutamol":[183],"use":[184],"reduced":[186],"(p<0.05)":[187],"groups":[190,203],"except":[191],"0.75":[193],"mg.":[194],"Adverse":[195],"events":[196],"similar":[198,254],"frequency":[200],"between":[201],"placebo,":[205],"no":[207],"differences":[208],"ECG":[210],"outcome":[213],"measures.":[214],"Conclusions:":[215],"sustained":[218],"over":[220,236],"weeks.":[222],"There":[223],"statistically":[228],"improvement":[232],"safety":[247],"profile":[248],"dose":[251],"levels":[252],"placebo.":[256]},"counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2019-01-01T00:00:00"}